EP 3468611 A1 20190417 - HUMAN FIBROBLAST GROWTH FACTOR 2 (FGF2) - CYTOTOXIC DRUG CONJUGATES FOR TARGETED THERAPY OF FGFR-RELATED CANCERS
Title (en)
HUMAN FIBROBLAST GROWTH FACTOR 2 (FGF2) - CYTOTOXIC DRUG CONJUGATES FOR TARGETED THERAPY OF FGFR-RELATED CANCERS
Title (de)
HUMANER FIBROBLASTENWACHSTUMSFAKTOR 2 (FGF2) - ZYTOTOXISCHE ARZNEIMITTELKONJUGATE ZUR GEZIELTEN THERAPIE VON FGFR-BEZOGENEN KREBSARTEN
Title (fr)
CONJUGUÉS DE FACTEUR DE CROISSANCE DES FIBROBLASTES 2 HUMAIN (FGF2) ET DE MÉDICAMENT CYTOTOXIQUE POUR LE TRAITEMENT CIBLÉ DE CANCERS LIÉS AU FGFR
Publication
Application
Priority
- PL 41754416 A 20160613
- IB 2016058083 W 20161229
Abstract (en)
[origin: WO2017216620A1] The subject invention provides strategy for destroying cancer cells using targeting molecules fused with highly cytotoxic agents. A natural ligand of FGF receptor, the fibroblast growth factor 2 (FGF2) or engineered variants thereof are used for bioconjugation with a potent cytotoxic compound such as monomethyl auristatin E (MMAE) or auristatin Y to establish a delivery technique for effective killing cancer cells overexpressing FGFR. The FGF2 molecule and its engineered variants act as a delivery molecules specifically directing cytotoxic drug to cancer cell by binding to FGF receptors and in consequence, being internalized into the cell. Obtained conjugates showed a prominent cytotoxic effect toward FGFR – related cancer cells.
IPC 8 full level
A61K 47/60 (2017.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); C07K 14/50 (2006.01)
CPC (source: EP)
A61K 47/60 (2017.07); A61K 47/642 (2017.07); A61P 35/00 (2017.12); C07K 14/50 (2013.01); C07K 14/503 (2013.01)
Citation (search report)
See references of WO 2017216620A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2017216620 A1 20171221; EP 3468611 A1 20190417; PL 238516 B1 20210830; PL 417544 A1 20171218
DOCDB simple family (application)
IB 2016058083 W 20161229; EP 16831758 A 20161229; PL 41754416 A 20160613